TNGX
Tango Therapeutics, Inc.
Next earnings Aug 3, 2026 · consensus $-0.33 EPS
Last earnings +8.6% on 2026-05-13
$31.47
▲ +4.41%$31.47▲ +509.88%
over 1Y
L $4.92EODHDH $32.90
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.4%
1W+10.4%
1M+60.2%
3M+63.4%
YTD+252.4%
1Y+509.9%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 18 analysts
Buy
Pre-product precision-oncology biotech burning ~$139M/yr at 64x sales — binary clinical risk, not investable on fundamentals.
Tango Therapeutics is a clinical-stage precision-oncology company with, in its own words, a limited operating history, no products approved for commercial sale, and no revenue from product sales. The $62.4M of FY2025 revenue (+48.3%) is collaboration income, not drug sales, and the company has never successfully completed any clinical trials. The financials reflect a pre-commercial biotech: operating loss of -$111M, net loss of -$102M (diluted EPS -$0.87), and an accumulated deficit (retained earnings) of -$603M. Operating margin is -178.4% and return on equity -29.3%.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $37.0M | $24.9M | $36.5M | $42.1M | $62.4M |
| Gross profit | — | — | — | — | — |
| Operating income | -$58.2M | -$111M | -$114M | -$146M | -$111M |
| Net income | -$58.2M | -$108M | -$102M | -$130M | -$102M |
| Diluted EPS | -$0.94 | -$1.23 | -$1.08 | -$1.19 | -$0.87 |
| Net margin | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.38B
EV / EBITDA—
EV / Sales70.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.3%
FCF yield-3.1%
Quality & risk
ROIC (est.)-25.4%
Free cash flow-$140M
Total debt—
Net cash$112M
Altman Z-Score49.43 safe
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+32.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-23
- 8-K Material agreement2026-06-10
- 8-K Reg FD disclosure2026-06-08
- 8-K Shareholder vote2026-06-04
- 8-K Officer / director change2026-05-13
- 10-Q Quarterly report2026-05-13
- 8-K Officer / director change2026-05-08
- DEF 14A Proxy statement2026-04-17
- 10-K Annual report2026-03-05
Recent filings
all on EDGAR ↗4Period ending 2026-06-192026-06-23open ↗3Period ending 2026-06-192026-06-23open ↗8-KPeriod ending 2026-06-192026-06-23open ↗144Filing2026-06-17open ↗144Filing2026-06-11open ↗8-KPeriod ending 2026-06-092026-06-10open ↗424B5Filing2026-06-10open ↗144Filing2026-06-10open ↗FWPFiling2026-06-10open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗
Frequently asked
- Is Tango Therapeutics, Inc. (TNGX) a buy?
- TNGX currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-product precision-oncology biotech burning ~$139M/yr at 64x sales — binary clinical risk, not investable on fundamentals.
- What is Tango Therapeutics, Inc.'s quality score?
- TNGX scores 48.29411764705881/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001819133, latest 10-Q filed 2026-05-13) · EODHD · analysis by claude-code · as of 6/21/2026, 8:47:55 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.